Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Austar Lifesciences Ltd. (HK:6118)
HKEX:6118
Holding HK:6118?
Track your performance easily
6118 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$0.45 - HK$2.20
Previous CloseHK$0.55
Volume410.00K
Average Volume (3M)170.03K
Market Cap
HK$281.92M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Apr 01, 2025EPS EstimateN/A
Last Dividend Ex-Date
May 19, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares OutstandingN/A
10 Day Avg. Volume215,400
30 Day Avg. Volume170,033
Standard Deviation0.24
R-Squared0.04
Alpha0.00183
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Austar Lifesciences Ltd. News
PremiumCompany Announcements
Austar Lifesciences Acquires Full Control of Target Company
PremiumCompany Announcements
Austar Lifesciences Ends Relocation Agreement
PremiumCompany Announcements
Austar Lifesciences Returns to Profitability in H1 2024
PremiumCompany Announcements
Austar Lifesciences Prepares for Key Financial Review
PremiumCompany Announcements
Austar Lifesciences Anticipates Profit Turnaround
PremiumCompany Announcements
Austar Lifesciences Shareholders Approve All Resolutions6118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.45 and its highest was HK$2.20 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Currently, no data Available
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
Austar Lifesciences Ltd.’s upcoming earnings report date is Apr 01, 2025 which is in 98 days.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Aug 27, 2024. The company reported HK$0.012 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.012.
Is Austar Lifesciences Ltd. overvalued?
According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
---
Austar Lifesciences Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.83%
12-Months-Change
Fundamentals
Return on Equity
1.62%
Trailing 12-Months
Asset Growth
-7.56%
Trailing 12-Months
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.
---
Technical Analysis
JY Grandmark Holdings Limited
―
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H
―
Classified Group (Holdings) Limited
―
Qingdao Port International Co Ltd Class H
―
---